MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Complicated Intra-abdominal Infection
Conditions
Complicated Intra-abdominal Infection
Trial Timeline
Jan 1, 2004 → Sep 1, 2004
NCT ID
NCT00157898About MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole is a approved stage product being developed by Merck for Complicated Intra-abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00157898. Target conditions include Complicated Intra-abdominal Infection.
What happened to similar drugs?
3 of 20 similar drugs in Complicated Intra-abdominal Infection were approved
Approved (3) Terminated (3) Active (16)
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00157898 | Approved | Completed |
Competing Products
20 competing products in Complicated Intra-abdominal Infection